Early Access

10-QPeriod: Q3 FY2024

INTUITIVE SURGICAL INC Quarterly Report for Q3 Ended Sep 30, 2024

Filed October 18, 2024For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) reported strong third-quarter results for the period ending September 29, 2024, demonstrating robust top-line growth and improving profitability. Total revenue surged 17% year-over-year to $2.04 billion, fueled by significant increases in both instruments and accessories revenue (+18%) and systems revenue (+17%). This growth was primarily driven by a 17% increase in total da Vinci procedures and the successful launch and placement of 110 new da Vinci 5 systems during the quarter. The company also reported a substantial increase in operating income, up 24% to $577 million, reflecting improved gross margins to 67.4% and effective management of operating expenses. This strong financial performance, coupled with a growing installed base of da Vinci and Ion systems, positions Intuitive Surgical favorably. The company maintains a healthy balance sheet with $8.31 billion in cash, cash equivalents, and investments, providing ample resources for continued investment in innovation and global expansion.

Financial Statements
Beta

Key Highlights

  • 1Total revenue increased 17% year-over-year to $2.04 billion, driven by strong performance in instruments and accessories, systems, and service revenue.
  • 2Da Vinci procedures grew 18% year-over-year, demonstrating continued adoption and utilization of the company's robotic surgical systems.
  • 3Systems revenue saw a 17% increase, supported by a 17% rise in da Vinci system placements (379 systems placed in Q3 2024) and the introduction of the da Vinci 5 system.
  • 4Operating income grew significantly by 24% to $577 million, reflecting improved gross profit margins and disciplined expense management.
  • 5The installed base of da Vinci systems expanded by 15% to approximately 9,539 systems, indicating sustained market penetration.
  • 6Ion system procedures saw substantial growth of 73%, reflecting increasing adoption of the endoluminal system.
  • 7The company ended the quarter with a strong liquidity position, holding $8.31 billion in cash, cash equivalents, and investments.

Frequently Asked Questions